Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Positive and negative regulation of APP amyloidogenesis by sumoylation.

Li Y, Wang H, Wang S, Quon D, Liu YW, Cordell B.

Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):259-64. Erratum in: Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):9102.

2.

Modulation of Abeta generation by small ubiquitin-like modifiers does not require conjugation to target proteins.

Dorval V, Mazzella MJ, Mathews PM, Hay RT, Fraser PE.

Biochem J. 2007 Jun 1;404(2):309-16.

3.

Profiles of SUMO and ubiquitin conjugation in an Alzheimer's disease model.

McMillan LE, Brown JT, Henley JM, Cimarosti H.

Neurosci Lett. 2011 Sep 20;502(3):201-8. doi: 10.1016/j.neulet.2011.07.045.

4.

Sumoylation of amyloid precursor protein negatively regulates Abeta aggregate levels.

Zhang YQ, Sarge KD.

Biochem Biophys Res Commun. 2008 Oct 3;374(4):673-8. doi: 10.1016/j.bbrc.2008.07.109.

5.

SUMO-1 modification increases human SOD1 stability and aggregation.

Fei E, Jia N, Yan M, Ying Z, Sun Q, Wang H, Zhang T, Ma X, Ding H, Yao X, Shi Y, Wang G.

Biochem Biophys Res Commun. 2006 Aug 25;347(2):406-12.

PMID:
16828461
6.

The gap junction channel protein connexin 43 is covalently modified and regulated by SUMOylation.

Kjenseth A, Fykerud TA, Sirnes S, Bruun J, Yohannes Z, Kolberg M, Omori Y, Rivedal E, Leithe E.

J Biol Chem. 2012 May 4;287(19):15851-61. doi: 10.1074/jbc.M111.281832.

7.

Small ubiquitin-like modifier 3-modified proteome regulated by brain ischemia in novel small ubiquitin-like modifier transgenic mice: putative protective proteins/pathways.

Yang W, Sheng H, Thompson JW, Zhao S, Wang L, Miao P, Liu X, Moseley MA, Paschen W.

Stroke. 2014 Apr;45(4):1115-22. doi: 10.1161/STROKEAHA.113.004315.

8.
9.

SUMO and Alzheimer's disease.

Lee L, Sakurai M, Matsuzaki S, Arancio O, Fraser P.

Neuromolecular Med. 2013 Dec;15(4):720-36. doi: 10.1007/s12017-013-8257-7. Review.

10.
11.

Small ubiquitin-like modifier 1-3 conjugation [corrected] is activated in human astrocytic brain tumors and is required for glioblastoma cell survival.

Yang W, Wang L, Roehn G, Pearlstein RD, Ali-Osman F, Pan H, Goldbrunner R, Krantz M, Harms C, Paschen W.

Cancer Sci. 2013 Jan;104(1):70-7. doi: 10.1111/cas.12047. Erratum in: Cancer Sci. 2013 Feb;104(2):274.

12.
13.

Stress-induced inactivation of the c-Myb transcription factor through conjugation of SUMO-2/3 proteins.

Sramko M, Markus J, Kabát J, Wolff L, Bies J.

J Biol Chem. 2006 Dec 29;281(52):40065-75.

14.
15.

SUMOylation of hypoxia-inducible factor-1alpha reduces its transcriptional activity.

Berta MA, Mazure N, Hattab M, Pouysségur J, Brahimi-Horn MC.

Biochem Biophys Res Commun. 2007 Aug 31;360(3):646-52.

PMID:
17610843
16.

A proline-90 residue unique to SUMO-4 prevents maturation and sumoylation.

Owerbach D, McKay EM, Yeh ET, Gabbay KH, Bohren KM.

Biochem Biophys Res Commun. 2005 Nov 18;337(2):517-20.

PMID:
16198310
17.

Small ubiquitin-related modifier (SUMO)-1 promotes glycolysis in hypoxia.

Agbor TA, Cheong A, Comerford KM, Scholz CC, Bruning U, Clarke A, Cummins EP, Cagney G, Taylor CT.

J Biol Chem. 2011 Feb 11;286(6):4718-26. doi: 10.1074/jbc.M110.115931.

19.

Covalent modification by SUMO is required for efficient disruption of PML oncogenic domains by Kaposi's sarcoma-associated herpesvirus latent protein LANA2.

Marcos-Villar L, Campagna M, Lopitz-Otsoa F, Gallego P, González-Santamaría J, González D, Rodriguez MS, Rivas C.

J Gen Virol. 2011 Jan;92(Pt 1):188-94. doi: 10.1099/vir.0.024984-0.

PMID:
20881090
20.

Repression of the Transactivating Capacity of the Oncoprotein PLAG1 by SUMOylation.

Van Dyck F, Delvaux EL, Van de Ven WJ, Chavez MV.

J Biol Chem. 2004 Aug 20;279(34):36121-31.

Supplemental Content

Support Center